Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2005 August;96(4) > Minerva Medica 2005 August;96(4):303-16

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

REVIEWS  


Minerva Medica 2005 August;96(4):303-16

language: English

Pulmonary arterial hypertension: pathobiology, diagnosis and treatment

Golpon H. A., Welte T., Hoeper M. M.


PDF  


Pulmonary arterial hypertension (PAH) is defined as a group of diseases characterized by a progressive increase of pulmonary vascular resistance leading to right ventricular failure. It includes a variety of pulmonary hypertensive diseases with different etiologies but similar clinical presentation. PAH is a disease of the small pulmonary arteries, characterized by progressive obliteration of the pulmonary vascular bed. Vasoconstriction, remodeling of the pulmonary vessel wall and thrombosis contribute to an increased pulmonary vascular resistance. Major advances in our understanding of the mechanism of disease development have been achieved over the past decade. Several of these new insights have led to the development and clinical application of novel treatments that includes new classes of drugs such as prostanoids, endothelin receptor antagonists and type 5 phosphodiesterase inhibitors.

top of page

Publication History

Cite this article as

Corresponding author e-mail